Purpose Epidemiologic study of sarcoidosis utilizing electronic databases has been increasingly popular. However, the accuracy of diagnostic codes for sarcoidosis is unknown. Methods The medical record-linkage system of the Rochester Epidemiology Project was searched to identify all potential adult cases of sarcoidosis between January 1, 1995 and December 31, 2013 in Olmsted County, Minnesota, using the International Classification of Diseases, Ninth Revision (ICD-9) code 135 (sarcoidosis). Complete medical records of those potential cases were individually reviewed. The diagnosis of sarcoidosis was confirmed by the presence of non-caseating granuloma on histopathology, radiographic findings of intrathoracic sarcoidosis, and compatible clinical presentations. Positive predictive value (PPV) was estimated as the number of patients verified to have sarcoidosis divided by the number of patients with a diagnostic code for sarcoidosis. Results The study cohort included 366 patients with at least one code for sarcoidosis. Of these, 224 cases of confirmed sarcoidosis were identified, resulting in PPV of 61.2% (95% CI 56.0-66.2%). A total of 268 patients in the database had a code for sarcoidosis on least two occasions separated by at least 30 days. Of these, there were 205 cases of confirmed sarcoidosis. The PPV for having the code at least twice was 76.5% (95% CI 71.0-81.4%). Conclusions The PPV of ICD-9 code for sarcoidosis is relatively low and, thus, further verification is required for studies using electronic databases.
Introduction
Epidemiologic and clinical research utilizing electronic databases has been increasingly popular over the past two decades [1] . The advantages of this approach include the convenience and speed in conducting analyses on large number of subjects which would allow detection of smallsize associations and provide more precise effect estimates. However, the accuracy of diagnostic codes is generally limited. Studies on diagnostic codes for common pulmonary diseases, such as chronic obstructive pulmonary disease, asthma, and venous thromboembolism, revealed positive predictive values of only 50-70% [2] [3] [4] . The current study was conducted with the aim to assess the accuracy of diagnostic coding for sarcoidosis. Descriptive statistics were used to summarize the data. Positive predictive value (PPV) was estimated as the number of patients verified to have sarcoidosis divided by the number of patients with a diagnostic code for sarcoidosis. Ninety-five percent confidence intervals (CI) were calculated using the exact binomial method. Logistic regression models were used to examine differences in PPV according to age, sex, and calendar year. Additional analysis was conducted to estimate the PPV for patients with the occurrence of the code for at least twice.
Results
The study cohort included 366 patients with at least one code for sarcoidosis (mean age 49.7 years, 56% female, 85% Caucasian, and 9% African American). Of these, 224 cases of confirmed sarcoidosis were identified, resulting in PPV of 61.2% (95% CI 56.0-66.2%). The PPVs by sex and age group are described in Table 1 . The PPV for females was significantly lower than males (56.4 vs. 67.3%; p = 0.034). No significant trends in PPV over calendar year (p = 0.18) or age (p = 0.55) were observed. A total of 268 patients in the database had a code for sarcoidosis on least two occasions separated by at least 30 days; of these, there were 205 cases of confirmed sarcoidosis. The PPV for having the code at least twice was 76.5% (95% CI 71.0-81.4%).
Discussion
The current study is the first to utilize a population-based cohort to assess the accuracy of diagnostic coding for sarcoidosis. Similar to other pulmonary diseases [2] [3] [4] , the PPV of ICD-9 coding for sarcoidosis was relatively low, which indicates that misclassification of patients with sarcoidosis is common in coding-based studies. Thus, the validity of the results of such studies depends on how vigorously the diagnosis of sarcoidosis was verified. Verification by individual medical record review is generally associated with the highest accuracy. However, this approach is often not feasible, particularly for studies using large electronic medical databases. The current study suggests that requiring the presence of the diagnostic code at least twice could be a reasonable alternative as it improved the PPV to over 75%, although this approach missed 19 patients (8%) with sarcoidosis.
The PPV of ICD-9 coding for sarcoidosis among females in this study was lower than for males. Different patterns of healthcare utilization between the two sexes may be the contributing factors as 51% males with sarcoidosis in this cohort had pulmonary symptoms, whereas only 36% of females had them [6] , which suggests that sarcoidosis in females was incidentally found more often than in males.
The major strength of this study is the accuracy of the diagnosis of sarcoidosis that was individually verified by medical record, histopathology, and radiographic study review. The population-based design also allows capturing of the full spectrum of the severity of sarcoidosis in the community, unlike referral-based cohort that tends to capture only cases with more severe disease. However, generalizability of the results to other databases could be limited as the pattern of diagnosis and coding could vary between healthcare systems. The clinical manifestations and severity of sarcoidosis vary considerably across ethnic groups [7, 8] and the patients in this study were predominately Caucasians. Finally, PPV is dependent on pre-test probability and could be significantly higher and lower in the populations/databases with higher and lower prevalence of sarcoidosis, respectively.
Conclusion
In conclusion, the PPV of ICD-9 code for sarcoidosis is relatively low and, thus, further verification is required for studies using electronic databases.
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